Ponsegromab

Leap Therapeutics' novel GDF-15 neutralizing antibody FL-501 demonstrated superior efficacy in preclinical models, fully restoring body composition and reversing key indicators of cancer cachexia.

ALX Oncology's ASPEN-06 Phase 2 trial evaluates evorpacept, a CD47-blocker, in HER2-positive advanced gastric cancer patients who have been previously treated.

Phase 2 trial data reveals ponsegromab significantly increased weight gain in cancer patients with elevated GDF-15 levels compared to placebo over 12 weeks.

A clinical trial of dostarlimab showed a 100% complete response rate in patients with mismatch repair deficient, locally advanced rectal cancer, lasting over two years.

Pfizer's experimental antibody, ponsegromab, demonstrates potential in treating cancer-related cachexia, a wasting syndrome, by promoting weight gain.